-
Product Insights
African Trypanosomiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘African Trypanosomiasis - Drugs In Development, 2023’, provides an overview of the African Trypanosomiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for African Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) - Drugs In Development, 2023’, provides an overview of the Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Systemic Candidiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Systemic Candidiasis - Drugs In Development, 2023’, provides an overview of the Systemic Candidiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Aspergillosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Aspergillosis - Drugs In Development, 2023’, provides an overview of the Aspergillosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Aspergillosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Candidiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Candidiasis - Drugs In Development, 2023’, provides an overview of the Candidiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Trypanosomiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Trypanosomiasis - Drugs In Development, 2023’, provides an overview of the Trypanosomiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Mycoses – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycoses - Drugs In Development, 2023’, provides an overview of the Mycoses pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy for Non-Small Cell Lung Cancer in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cellular Immunotherapy for Non-Small Cell Lung Cancer in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cellular Immunotherapy For Non-Small Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-07209960 in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-07209960 in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-07209960 in Head And Neck Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Damistimagene Matitucel + Enistimagene Setitucel) in Metastatic Adenocarcinoma of The Pancreas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Damistimagene Matitucel + Enistimagene Setitucel) in Metastatic Adenocarcinoma of The Pancreas Drug Details:Damistimagene matitucel in a...